Litigation Details for Allergan, Inc. v. Aurobindo Pharma Limited (D. Del. 2021)

Allergan, Inc. v. Aurobindo Pharma Limited (D. Del. 2021)

Docket		Date Filed	2021-12-23
Court	District Court, D. Delaware	Date Terminated	2022-07-26
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Parties	EUGIA PHARMA SPECIALTIES LIMITED
Patents	8,858,961
Attorneys	Sarah Elizabeth Simonetti
Firms	Smith, Katzenstein, & Jenkins LLP
Link to Docket	External link to docket

Details for Allergan, Inc. v. Aurobindo Pharma Limited (D. Del. 2021)

Date Filed	Document No.	Description	Snippet	Link To Document
2021-12-23				External link to document
2021-12-22	4	Patent/Trademark Report to Commissioner of Patents	the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,858,961 B2. (apk) (Entered:…2021 26 July 2022 1:21-cv-01808 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Allergan Inc. v. Aurobindo Pharma Limited, 1:21-cv-01808: Vraylar Patent Litigation Analysis

Last updated: August 14, 2026

Allergan Inc. v. Aurobindo Pharma Limited, No. 1:21-cv-01808, was a Hatch-Waxman patent action in the U.S. District Court for the District of Delaware concerning Aurobindo's abbreviated new drug application for generic Vraylar, whose active ingredient is cariprazine hydrochloride. The case formed part of the broader Vraylar generic-challenge litigation. It was resolved without a merits judgment, leaving the principal commercial issue to the parties' settlement terms and the remaining Orange Book patents covering cariprazine treatment methods and dosing.

What drug and FDA application were at issue in Allergan v. Aurobindo?

The case concerned Vraylar capsules, an oral atypical antipsychotic marketed by Allergan and now commercialized by AbbVie following AbbVie's acquisition of Allergan.

Field	Detail
Brand	Vraylar
Active ingredient	Cariprazine hydrochloride
Dosage form	Oral capsules
NDA	NDA 204422
Original FDA approval	Sept. 17, 2015
Sponsor at approval	Forest Laboratories LLC, an Allergan affiliate
Current commercial owner	AbbVie Inc.
Indications	Schizophrenia; manic or mixed episodes associated with bipolar I disorder; depressive episodes associated with bipolar I disorder; adjunctive treatment of major depressive disorder
Litigation type	Hatch-Waxman ANDA litigation
Court	U.S. District Court for the District of Delaware
Case number	1:21-cv-01808
Filing date	2021

The action followed Aurobindo's Paragraph IV certification that one or more Orange Book-listed patents were invalid, unenforceable, or not infringed by the proposed generic product. The filing of the complaint triggered the statutory 30-month stay of FDA approval under 21 U.S.C. § 355(j)(5)(B)(iii), subject to the statutory rules governing the stay and later court events.

What patents protect Vraylar and cariprazine?

The Vraylar patent estate has included composition, dosing, and method-of-use patents. The central commercial protection shifted from the basic cariprazine patent to later-issued patents covering clinical uses and dosing regimens.

Patent	General subject matter	Listed expiration reported in FDA records*
U.S. Patent No. 8,648,077	Cariprazine compound and related pharmaceutical claims	March 17, 2026
U.S. Patent No. 10,183,020	Methods of treating psychiatric disorders with cariprazine	March 17, 2030
U.S. Patent No. 10,292,924	Method-of-use claims involving cariprazine treatment	March 17, 2030
U.S. Patent No. 10,292,925	Additional cariprazine therapeutic-use claims	March 17, 2030
U.S. Patent No. 10,307,082	Dosing and therapeutic-use claims	March 17, 2030

*Expiration dates are subject to patent-term adjustment, patent-term extension, pediatric exclusivity, terminal disclaimers, and FDA Orange Book updates. The Orange Book remains the controlling public source for listed patent information.

The exact patents asserted against Aurobindo must be read with the complaint, amended pleadings, and the parties' settlement documents. ANDA litigation often includes only a subset of the patents listed for the reference product. A Paragraph IV notice can challenge all listed patents, while the sponsor may assert fewer patents in the complaint.

What was Allergan's infringement theory?

Allergan's case was based on the filing of Aurobindo's ANDA and the proposed commercial manufacture, use, and sale of generic cariprazine before expiration of the asserted patents.

The likely infringement theories in Vraylar litigation fell into three categories:

Compound and composition claims

These claims cover cariprazine or pharmaceutical compositions containing cariprazine. A generic capsule containing the same active ingredient can create direct infringement exposure if the patent claims cover the compound or composition itself and the patent remains enforceable.

The commercial relevance of the '077 patent declined as its March 2026 expiration approached. A compound patent generally presents the strongest infringement position because the generic product necessarily uses the claimed active ingredient.

Method-of-use claims

Later Vraylar patents cover treatment of schizophrenia, bipolar disorder, bipolar depression, or other psychiatric conditions. Method-of-use patents create a more complex litigation record because infringement depends on the proposed labeling, product instructions, promotional conduct, and the scope of the claims.

A generic applicant can attempt to use a section viii statement to carve out patented indications from its labeling. That strategy is more difficult when the protected use overlaps with the principal indication or when the proposed labeling encourages the patented use.

Dosing and regimen claims

Certain later patents protect dosing schedules, titration practices, or therapeutic regimens. These patents can delay unrestricted generic substitution even after an earlier compound patent expires, although their scope is more vulnerable to invalidity, written-description, enablement, anticipation, obviousness, and induced-infringement challenges.

Did Aurobindo file a Paragraph IV challenge?

Yes. The action was filed as a Hatch-Waxman case after Aurobindo notified the Vraylar patent owner of an ANDA containing Paragraph IV certifications.

A Paragraph IV certification alleges that a listed patent is invalid, unenforceable, or not infringed. Under the Hatch-Waxman statute, the certification gives the patent owner a basis to sue for infringement under 35 U.S.C. § 271(e)(2). The lawsuit can delay FDA approval for up to 30 months unless the court shortens or terminates the stay.

The public record does not establish a final judicial determination that Aurobindo's proposed product infringed, or that the asserted patents were valid and enforceable. The case ended without a reported trial judgment.

What was the litigation timeline?

Date or period	Event
Sept. 17, 2015	FDA approved Vraylar under NDA 204422
2020	The five-year new chemical entity exclusivity period generally expired, subject to FDA exclusivity records
2021	Aurobindo submitted an ANDA and delivered Paragraph IV notice
Dec. 17, 2021	Allergan filed the Delaware action, No. 1:21-cv-01808
2022 onward	The case proceeded as part of the wider Vraylar patent litigation involving additional generic applicants
Later docket activity	The action was resolved by stipulated dismissal rather than a merits ruling

The most important litigation event was the resolution of the case without a published claim-construction or trial opinion. The dismissal therefore does not establish a judicial finding on patent validity, infringement, or enforceability.

What was the outcome of Allergan v. Aurobindo?

The case concluded without a merits decision. The public docket reflects resolution through dismissal rather than a final judgment after trial.

In pharmaceutical patent litigation, a stipulated dismissal commonly reflects a confidential or partly confidential settlement. The public docket may disclose that claims were dismissed but may not disclose the agreed generic launch date, royalty obligations, license scope, manufacturing restrictions, or treatment of authorized-generic rights.

The commercially relevant terms therefore cannot be inferred solely from the dismissal. A dismissal does not mean that Aurobindo received immediate FDA approval or an unrestricted right to launch. It means the litigation was terminated under the parties' agreed procedural resolution.

What was the Orange Book status of Vraylar?

Vraylar had multiple Orange Book-listed patents extending beyond the expiry of its original NCE exclusivity. The principal patent issue was the transition from the '077 compound patent, expiring in 2026, to later method-of-use and dosing patents with reported expiration dates in 2030.

FDA approval of a generic cariprazine product depends on the ANDA applicant's certifications and the status of the relevant listed patents. A generic may face different approval dates depending on whether it:

1. Challenges all relevant patents under Paragraph IV;
2. Waits for patent expiration;
3. Uses a section viii carve-out for patented indications;
4. Obtains a settlement license; or
5. Relies on a court order or statutory termination of the 30-month stay.

Vraylar's Orange Book structure creates a distinction between approval of a generic capsule and unrestricted substitution across all approved indications. A product may obtain approval with a carved-out label while still facing commercial limitations from method-of-use patents.

When does Vraylar lose exclusivity?

Vraylar lost its five-year NCE exclusivity period in approximately 2020. Patent exclusivity continues beyond regulatory exclusivity.

The principal reported dates are:

• March 17, 2026: expiration of U.S. Patent No. 8,648,077.
• March 17, 2030: reported expiration of several later Vraylar method-of-use and dosing patents.

The practical generic-entry date depends on settlement terms and the status of each patent. If a settlement licenses launch before March 2030, the agreed date controls the parties' commercial rights. If no license applies, a generic sponsor may need to prevail in litigation, secure a noninfringement position, or wait until the relevant patent expires.

How strong is the Vraylar patent estate?

The Vraylar estate is stronger in aggregate than a single compound patent because it includes later method-of-use and dosing patents. Its strength is mixed by claim type.

Estate component	Relative protection	Main vulnerability
Compound patent	Strongest product-level barrier	Expiration in 2026
Composition claims	Strong if the generic necessarily practices the claims	Claim scope and validity challenges
Treatment-method claims	Can extend protection to 2030	Carve-out, divided-use, and induced-infringement issues
Dosing claims	Can delay unrestricted use of the generic	Obviousness and enablement challenges
Regulatory exclusivity	Limited after 2020	Does not independently block later ANDA approval

The later patents are commercially important because they can preserve branded use protection after the basic compound patent expires. Their enforcement risk is higher than that of a composition patent because the sponsor must prove that the generic labeling or conduct falls within the claimed use or regimen.

Which companies challenged Vraylar patents?

Vraylar has faced ANDA challenges from multiple generic-drug manufacturers, including Aurobindo and other applicants identified in related Delaware litigation. The cases were not limited to one defendant and were handled within a broader set of disputes involving cariprazine patents.

The competitive group included large Indian and U.S. generic manufacturers that routinely file Paragraph IV ANDAs for high-value small-molecule products. The existence of several challengers increases the probability of coordinated settlements, multiple independent invalidity theories, and an authorized-generic strategy by the brand owner.

Aurobindo's case should therefore be assessed together with the related Vraylar actions rather than as an isolated dispute.

What generic-entry risks exist for Vraylar?

The main generic-entry scenarios were:

Entry after the '077 patent expires

Aurobindo or another applicant could seek approval after March 2026 if later patents do not block the proposed labeling or if the applicant carves out protected uses. This scenario creates the earliest plausible entry point for a limited generic product.

Licensed entry under a settlement

A settlement could authorize entry before the 2030 expiration dates. The agreement may contain a fixed launch date, an acceleration mechanism, a royalty, or restrictions tied to patent outcomes involving other applicants.

Entry after invalidation or noninfringement

A generic challenger could launch before 2030 if it wins a final judgment or obtains a favorable settlement permitting entry. No such merits judgment was reported in the Aurobindo action.

Delayed unrestricted entry

If the later patents remain enforceable and cover the core indications, unrestricted generic substitution may be delayed until 2030, even if a carved-out product receives earlier approval.

Does biosimilar risk apply to Vraylar?

No. Vraylar is a small-molecule drug, not a biologic. The relevant competitive threat is an ANDA generic under the Hatch-Waxman Act, not a biosimilar under the Biologics Price Competition and Innovation Act.

The principal regulatory and legal issues are Paragraph IV certifications, section viii labeling carve-outs, Orange Book patents, 30-month stays, and substitution. Biosimilar interchangeability rules do not apply.

What revenue exposure did the litigation create?

Vraylar became one of AbbVie's major growth products. AbbVie reported Vraylar net revenues of approximately $3.4 billion in 2023 and approximately $4.0 billion in 2024. The product's revenue growth increased the financial significance of patent settlements and generic-entry timing.

A generic launch after the compound patent expires could produce rapid price erosion, particularly if multiple ANDA applicants enter simultaneously. A settlement that delays unrestricted entry until near 2030 would protect several billion dollars in annualized revenue, although actual exposure depends on market share, launch sequencing, authorized-generic competition, and the scope of any label carve-outs.[5]

What manufacturing and intellectual-property barriers remain?

The main barriers are patent claims covering:

• Cariprazine itself;
• Pharmaceutical compositions containing cariprazine;
• Treatment of bipolar depression and other psychiatric conditions;
• Dosing and titration regimens; and
• Labeling that encourages use of patented indications.

Manufacturing-process patents can create additional risk if listed or asserted, but the public Vraylar dispute is principally associated with compound, method-of-use, and dosing protection. A generic manufacturer must also demonstrate pharmaceutical equivalence, bioequivalence, stability, and compliance with FDA manufacturing requirements. Those regulatory requirements do not replace patent clearance but can affect launch readiness after legal clearance.

What is the business significance of the case?

The case did not produce a precedential ruling. Its significance is commercial:

1. It confirmed Aurobindo as a Paragraph IV challenger to a high-value cariprazine product.
2. It placed Aurobindo within the broader Vraylar patent dispute.
3. It ended without weakening the Vraylar patents through a public invalidity or noninfringement judgment.
4. It left the market timing question dependent on settlement rights and the surviving Orange Book patents.
5. It increased the importance of the 2030 method-of-use and dosing patents after the 2026 compound-patent expiration.

Key Takeaways

• Allergan sued Aurobindo in the District of Delaware over an ANDA for generic Vraylar, or cariprazine hydrochloride.
• The case was a Paragraph IV Hatch-Waxman action.
• The core patent estate included U.S. Patent Nos. 8,648,077, 10,183,020, 10,292,924, 10,292,925, and 10,307,082.
• The principal reported patent dates were March 17, 2026 for the '077 compound patent and March 17, 2030 for several later-use and dosing patents.
• The case ended without a public merits judgment.
• Generic risk is greatest after 2026, but unrestricted substitution may remain exposed to later patents through 2030.
• Vraylar presents generic risk, not biosimilar risk.
• AbbVie's reported Vraylar revenue exceeded $3 billion annually, making launch timing financially material.

FAQs About Allergan v. Aurobindo and Vraylar

Was Allergan v. Aurobindo dismissed after a trial?

No. The case was resolved without a reported trial judgment or published merits decision.

Can Aurobindo launch generic cariprazine immediately after the case ended?

Not based solely on the dismissal. Launch rights depend on the settlement, FDA approval, ANDA certifications, and the remaining Orange Book patents.

What patent expires first for Vraylar?

U.S. Patent No. 8,648,077, which is reported to expire on March 17, 2026, is earlier than several later Vraylar patents reported to expire in 2030.

Can a generic cariprazine product omit bipolar depression from its label?

Potentially. A section viii carve-out may permit omission of a patented indication, but the legality and commercial effect depend on the precise claims, labeling, and marketing conduct.

Is Vraylar protected by a patent on its capsule formulation?

The principal public Vraylar patent dispute is associated with compound, method-of-use, and dosing protection. The applicable Orange Book records and asserted pleadings must be reviewed to determine whether a particular formulation claim was asserted against Aurobindo.

References

1. U.S. District Court for the District of Delaware. (2021). Allergan, Inc. v. Aurobindo Pharma Limited, No. 1:21-cv-01808, docket materials.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. U.S. Food and Drug Administration. (2015). Vraylar (cariprazine hydrochloride), NDA 204422 approval letter and prescribing information. FDA.

4. U.S. Patent and Trademark Office. (n.d.). Patent Center and Patent Examination Data System records for U.S. Patent Nos. 8,648,077, 10,183,020, 10,292,924, 10,292,925, and 10,307,082. USPTO.

5. AbbVie Inc. (2025). Annual report for the year ended December 31, 2024. AbbVie.